| Literature DB >> 34200759 |
Raha Orfali1, Shagufta Perveen1, Muhammad Farooq Khan2, Atallah F Ahmed1,3, Mohammad A Wadaan2, Areej Mohammad Al-Taweel1, Ali S Alqahtani1,4, Fahd A Nasr4, Sobia Tabassum5, Paolo Luciano6, Giuseppina Chianese6, Jyh-Horng Sheu7,8, Orazio Taglialatela-Scafati6.
Abstract
The new asperorlactone (1), along with the known illudalane sesquiterpene echinolactone D (2), two known pyrones, 4-(hydroxymethyl)-5-hydroxy-2H-pyran-2-one (3) and its acetate 4, and 4-hydroxybenzaldehyde (5), were isolated from a culture of Aspergillus oryzae, collected from Red Sea marine sediments. The structure of asperorlactone (1) was elucidated by HR-ESIMS, 1D, and 2D NMR, and a comparison between experimental and DFT calculated electronic circular dichroism (ECD) spectra. This is the first report of illudalane sesquiterpenoids from Aspergillus fungi and, more in general, from ascomycetes. Asperorlactone (1) exhibited antiproliferative activity against human lung, liver, and breast carcinoma cell lines, with IC50 values < 100 µM. All the isolated compounds were also evaluated for their toxicity using the zebrafish embryo model.Entities:
Keywords: Aspergillus oryzae; antiproliferative activity; illudalane sesquiterpenes; marine fungus; zebrafish toxicity
Mesh:
Substances:
Year: 2021 PMID: 34200759 PMCID: PMC8230370 DOI: 10.3390/md19060333
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Chemical structures of metabolites isolated from A. oryzae.
1H (700 MHz) and 13C (175 MHz) NMR data for asperorlactone (1) in CD3OD.
| Positions | δH (Mult., | δC, Type |
|---|---|---|
| 1a | 2.83 (overlapped) | 46.5, CH2 |
| 1b | 2.81 (d, 17.5) | |
| 2 | - | 150.1, C |
| 3 | - | 132.2, C |
| 4 | - | 136.2, C |
| 5 | 4.95 (dd, 1.0, 2.1) | 60.8, CH |
| 6 | 4.63 (dd, 1.0, 12.0) | 72.7, CH2 |
| 4.52 (dd, 2.1, 12.0) | ||
| 7 | - | 166.5, C |
| 8 | - | 122.7, C |
| 9 | 7.75 (s) | 123.1, CH |
| 10 | - | 144.3, C |
| 11 | 2.82 (overlapped) | 47.1, CH2 |
| 12 | - | 39.3, C |
| 13 | 2.37 (s) | 13.1, CH3 |
| 14 | 1.19 (s) | 27.5, CH3 |
| 15 | 1.19 (s) | 27.5, CH3 |
Figure 2COSY (blue) and key HMBC (red arrows) correlations for compound 1.
Figure 3The reasonably populated conformers 1a–1c of 1 and their calculated Boltzmann population.
Figure 4Experimental ECD curve of asperorlactone (red) and calculated ECD curves for R-1 (black) and S-1 (green).
Figure 5Postulated biosynthesis of asperorlactone (1).
Antiproliferative activity of compounds 1–5 against three human cancer cell lines.
| Compound | IC50 (µM) for the Different Carcinoma Cell Lines | ||
|---|---|---|---|
| A549 (Lung) | HepG2 (Liver) | MCF-7 (Breast) | |
|
| 72.7 ± 1.1 | 86.6 ± 3.2 | 106.5 ± 4.2 |
|
| 55.7 ± 2.5 | 148.4 ± 5.6 | 128.0 ± 2.8 |
|
| 208.5 ± 6.8 | 220.4 ± 3.6 | 225.4 ± 5.1 |
|
| 89.4 ± 2.3 | 126.8 ± 6.4 | 170.7 ± 4.5 |
|
| 97.5 ± 2.6 | 242.6 ± 6.4 | 158.2 ± 5.5 |
| Doxorubicin | 2.1 ± 0.08 | 2.2 ± 0.15 | 1.9 ± 0.05 |
Figure 6In vivo screening of compounds 1–5 in zebrafish embryos. Representative micrograph of embryos at 3 days poster fertilization, which were treated with compounds 1–5. The zebrafish embryos treated with compounds 2, 3, and 5 developed normally, and there were no obvious differences in morphology and growth between control and treated embryos. The zebrafish embryos treated with >200 µM of 1, however, had cardiac edema and cardiac hypertrophy (black arrow). The zebrafish embryos treated with compound 4 developed normally but were found dead on day 2. All the images are in same magnification, scale is 200 µm.